Monoclonal Antibodies for Metastatic Colorectal Cancer
Name of the Trial
Why This Trial Is Important
In this trial, patients will receive one of two targeted agents, or a combination of the two, that were recently approved by the U.S. Food and Drug Administration for use with combination chemotherapy in the treatment of metastatic colorectal cancer.
The two targeted agents, bevacizumab (Avastin) and cetuximab (Erbitux), are monoclonal antibodies that seek out and block the activity of different proteins important for tumor cell growth and spread. These proteins, vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR), respectively, are often found in much greater abundance on cancer cells than on normal cells.
"We want to see if combining these agents along with standard chemotherapy can help these patients live longer and possibly shrink their tumors enough to allow potentially curative surgical treatment," said Dr. Venook.
Who Can Join This Trial
Researchers will enroll 2,300 patients with metastatic colorectal cancer who have not received prior treatment. See the list of eligibility criteria at http://cancer.gov/clinicaltrials/CALGB-C80405. This clinical trial is eligible for special Medicare coverage.
Study Sites and Contact Information
An archive of "Featured Clinical Trial" columns is available at http://cancer.gov/clinicaltrials/ft-all-featured-trials.